Compare EPAM Systems Inc (EPAM) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs GSK plc — how do they compare? EPAM Systems Inc trades at $99.88 (market cap $5.15B), while GSK plc trades at $50.37 (market cap $102.60B). The key difference: GSK plc is far larger — about 19.9× EPAM Systems Inc's market cap, and GSK plc pays a 3.57% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| EPAM | GSK | |
|---|---|---|
Market Cap | $5.15B | $102.60B |
Sector | Technology | Health |
52-Week High | $221.40 | $61.18 |
52-Week Low | $76.04 | $38.96 |
Enterprise Value | $4.52B | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $100.29, up 3.0% with recent earnings beats but faces technical bearish signals. The company reported strong Q2 2026 results with EPS of $3.38 beating estimates, though revenue guidance was lowered due to North American softness. Valuation appears attractive with P/E of 13.55 and P/S of 0.97, while profitability metrics remain solid with 7.15% net margin.
The stock presents a value opportunity with analyst consensus target of $117.27 (17% upside), but faces near-term headwinds from reduced revenue guidance and technical weakness. Key risks include slowing demand in core markets, while the OpenAI partnership offers AI growth potential. Institutional sentiment remains positive with 65% buy ratings.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
